
    
      To determine whether a strategy of enhanced information about the risks of high plasma
      low-density lipoprotein cholesterol (LDL-C) and the importance of lipid-lowering medication
      together with close follow-up and motivational interviewing is superior than usual care in
      achieving LDL-C therapeutic targets, as set by current practice guidelines (LDL-C <70 mg/dL
      or >50% reduction from baseline LDL-C) in patients with acute coronary syndromes.
    
  